Affimed N.V. receives delisting notice from Nasdaq, trading to be suspended on May 20, 2025. Securities to be delisted.

Affimed N.V., a company focusing on immuno-oncology and listed on Nasdaq under the ticker symbol AFMD, has recently received notification from the Nasdaq Listing Qualifications Department regarding the suspension of trading for its common shares. In accordance with Nasdaq rules, trading will cease on May 20, 2025, and a delisting notice will be filed with the U.S. Securities Exchange Commission. This action is being taken under Nasdaq Listing Rule 5101, 5110(b), and IM-5101-1. Affimed N.V. aims to empower cancer patients by enhancing their natural ability to combat the disease.